BIO-RAD LABORATORIES -CL B (BIO.B) Stock Price & Overview

NYSE:BIO.B • US0905721082

Current stock price

299.45 USD
+22.45 (+8.1%)
Last:

The current stock price of BIO.B is 299.45 USD. Today BIO.B is up by 8.1%. In the past month the price increased by 19.74%. In the past year, price decreased by -63.42%.

BIO.B Key Statistics

52-Week Range225.29 - 814.34
Current BIO.B stock price positioned within its 52-week range.
1-Month Range247.05 - 321.12
Current BIO.B stock price positioned within its 1-month range.
Market Cap
8.082B
P/E
30.19
Fwd P/E
29.02
EPS (TTM)
9.92
Dividend Yield
N/A

BIO.B Stock Performance

Today
+8.1%
1 Week
+6.21%
1 Month
+19.74%
3 Months
-16.13%
Longer-term
6 Months -19.31%
1 Year -63.42%
2 Years -6.61%
3 Years -38.18%
5 Years -42.71%
10 Years +99.54%

BIO.B Stock Chart

BIO-RAD LABORATORIES -CL B / BIO.B Daily stock chart

BIO.B Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BIO.B. When comparing the yearly performance of all stocks, BIO.B is a bad performer in the overall market: 92.66% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BIO.B Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BIO.B. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIO.B Earnings

On February 12, 2026 BIO.B reported an EPS of 2.51 and a revenue of 693.20M. The company missed EPS expectations (-7.97% surprise) and missed revenue expectations (-0.35% surprise).

Next Earnings DateApr 30, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$2.51
Revenue Reported693.2M
EPS Surprise -7.97%
Revenue Surprise -0.35%

BIO.B Forecast & Estimates

10 analysts have analysed BIO.B and the average price target is 313.75 USD. This implies a price increase of 4.77% is expected in the next year compared to the current price of 299.45.

For the next year, analysts expect an EPS growth of 4.02% and a revenue growth 2.04% for BIO.B


Analysts
Analysts76
Price Target313.75 (4.78%)
EPS Next Y4.02%
Revenue Next Year2.04%

BIO.B Groups

Sector & Classification

Index Membership

BIO.B Financial Highlights

Over the last trailing twelve months BIO.B reported a non-GAAP Earnings per Share(EPS) of 9.92. The EPS decreased by -3.78% compared to the year before.


Income Statements
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Industry RankSector Rank
PM (TTM) 29.42%
ROA 7.18%
ROE 10.2%
Debt/Equity 0.16
Chartmill High Growth Momentum
EPS Q2Q%-13.45%
Sales Q2Q%3.85%
EPS 1Y (TTM)-3.78%
Revenue 1Y (TTM)0.65%

BIO.B Ownership

Ownership
Inst Owners90.49%
Shares26.99M
Float18.35M
Ins Owners8.11%
Short Float %N/A
Short RatioN/A

About BIO.B

Company Profile

BIO.B logo image Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,450 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Company Info

IPO: 1980-03-17

BIO-RAD LABORATORIES -CL B

1000 Alfred Nobel Dr

Hercules CALIFORNIA US

CEO: Norman Schwartz

Employees: 7450

BIO.B Company Website

BIO.B Investor Relations

Phone: 15107247000

BIO-RAD LABORATORIES -CL B / BIO.B FAQ

What does BIO-RAD LABORATORIES -CL B do?

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,450 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.


Can you provide the latest stock price for BIO-RAD LABORATORIES -CL B?

The current stock price of BIO.B is 299.45 USD. The price increased by 8.1% in the last trading session.


What is the dividend status of BIO-RAD LABORATORIES -CL B?

BIO.B does not pay a dividend.


What is the ChartMill technical and fundamental rating of BIO.B stock?

BIO.B has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


How is the valuation of BIO-RAD LABORATORIES -CL B (BIO.B) based on its PE ratio?

The PE ratio for BIO-RAD LABORATORIES -CL B (BIO.B) is 30.19. This is based on the reported non-GAAP earnings per share of 9.92 and the current share price of 299.45 USD.


Can you provide the number of employees for BIO-RAD LABORATORIES -CL B?

BIO-RAD LABORATORIES -CL B (BIO.B) currently has 7450 employees.


Can you provide the market cap for BIO-RAD LABORATORIES -CL B?

BIO-RAD LABORATORIES -CL B (BIO.B) has a market capitalization of 8.08B USD. This makes BIO.B a Mid Cap stock.